This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. 
Detailed procedures
At each study site, dedicated health workers and nurses were recruited and trained to enumerate and interview the eligible girls for socio-demographic and reproductive information, explain the study to the participating girls and their parents, obtain informed consent, administer the vaccines, document adverse events, and carry out follow-up procedures including collection of blood and cervical cell samples. The study was explained to a number of medical practitioners in the study clusters to make them aware of how to manage and/or refer the vaccinated girls if any reported to them with suspected adverse events. A 24-hour committed telephone line was provided to the participants to contact a study clinician in case any need for urgent medical attention arose.
Sample size calculation:
The sample size for the study was calculated to allow observation of 16 cases per group of high-grade cervical intraepithelial neoplasia (CIN 2-3) related to HPV 16/18 infection by 60 months. The required sample size was determined under the following assumptions:
1. The average cluster size of 100 girls 2. Annual drop-out rate of 5%
3.
For the intention-to-treat analysis, cumulative incidence rate of 1.3/10,000 in the threedose group of CIN 2-3 lesions caused by HPV 16 and 18
4.
The two doses of vaccine would be considered non-inferior to three doses if the increase in incidence of HPV 16/18-related CIN 2/3 or worse is less than three times the incidence within the three-dose group (i.e.<5.4/10,000). Under assumptions about the incidence in an unvaccinated population 13 with incidence of 40.7/10,000, this corresponds to a drop in absolute vaccine efficacy of less than 10 percentage points
5.
A power of 80% and a one-sided 95% confidence (α=0.05)
6.
Supposing that the cluster rates are log-normally distributed and that 95% of the clusters will have a true rate within a factor of 2 of the mean rate, using the incidence rate in the unvaccinated population, the estimated intracluster correlation coefficient would be 0.0008.
7.
Clusters of varying sizes with a coefficient of variation of 0.05
Under these assumptions, approximately 120 clusters and 12,000 girls (60 clusters and 6,000 girls per vaccination group) would be required.
However, a subgroup analysis in which the effect of the two-versus the three-dose will be compared in the age at entry categories 10-12, 12-15 and 16-18, is planned. Using Bonferroni adjustment, 20-21 i.e. taking α=1.67% (5%/3) as the level of significance for each of the subgroup analysis in order to be able to remain with a 5% level of significance for the overall effect, approximately 164 clusters and 16,400 girls (82 clusters and 8,200 girls per vaccination group) would be required for the subgroup analysis. This was calculated to allow observation of 22 CIN 2-3 cases per group related to HPV types 16 and 18 by 60 months.
Recruitment of the girls into the 2-dose and 3-dose groups and vaccination of eligible girls was initiated on 9 July 2009 and progressed satisfactorily until 8 April 2010, with more than 95% participation of the invited girls for vaccination, when the Indian authorities suspended all further recruitment and vaccination of subjects in all HPV vaccination trials in India, due to events unrelated to our study.
The suspension occasioned our having four groups of vaccinated girls: on days 1, 60 and 180 or more (three-dose group); on days one and 180 or more (two-dose group); on days one and 60
by default (two-dose/D group); and one dose only by default (one-dose/D group) (Figure 1 ).
We continue to follow-up these cohorts of girls with different doses to evaluate the outcomes in terms of immunogenicity, the frequency of HPV infection and cervical neoplasia.
Each participant is visited annually in her household and her health, well-being and vital status enquired into. Details regarding marriage, medically significant events, pregnancy, ante-and post-natal events, delivery and migration are collected and documented through a network of social workers, medical care providers, hospitals and relatives. Appointments are fixed for blood and cervical cell collection at designated periods.
To assess the sero-conversion, immunogenicity, antibody levels and durability of the immune response, blood samples were collected at baseline, 7, 12, 18, 24, 36, 48 and 60 months from a sample of the study population (Figure 1) .
A sub-set of EDTA plasma at baseline, 7, 12, 18, 24, 36 Antibody avidity, which reflects the degree of antibody affinity maturation, was measured in a modification of the HPV-L1 genotype specific binding antibody assay described above. After the first washing step the beads with the antigen-antibody complexes were incubated for 15 minutes with the chaotropic agent urea at 5 M concentration or washing buffer alone and then the standard washing procedure continued. Under this high urea concentration low-avidity antibodies can detach from the antigen and are subsequently washed away which results in lower MFI values as compared to the incubation with buffer alone.
Neutralizing antibodies specific for neutralizing-epitopes in HPV-L1 protein were measured using a highly sensitive, automated, high-throughput pseudovirion-based neutralization assay (PBNA)
with excellent repeatability and run-to-run reproducibility. 9 Bovine papillomavirus (BPV) pseudovirion assays were run as control to verify that the test serum is not toxic to the cells, which can mimic neutralization. The Lower Limit of Quantitation (LLOQ) for the HPV-PBNA is a reciprocal dilution of 40. A sample was classified as sero-negative if the PBNA titre was <50;
seropositive if the PBNA titre was ≥50 and ≥2 times the BPV titre; or sero-status indeterminate if the PBNA titre was ≥50 and <2 times the BPV titre.
Pelvic examination to collect cervical cell samples is being carried out in married girls 18 months after marriage or 6 months after delivery, whichever is earlier, and annually thereafter for 3 consecutive years.
A dedicated HPV testing laboratory was established at the RGCB, with technology transfer and quality assurance from the Infections and Cancer Biology Group at IARC and the DKFZ. The HPV genotyping method involved HPV type-specific E7 PCR bead-based multiplex genotyping (TS-MPG).
10, 11
The multiplex HPV type-specific E7 PCR utilizes HPV type-specific primers targeting the E7 region for the detection of 19 high-risk (HR) / probable HR-HPV types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68 a,b , 70, 73, 82), and two low-risk (LR)-HPV types (HPV 6 and 11), with detection limits ranging from 10 to 1000 copies of the viral genome.
The method was validated at RGCB under the supervision of scientists from IARC and the testing of cervical cell samples are carried out in RGCB.
The study has so far been monitored and evaluated by outcomes such as sero-conversion, comparison of the immunogenicity over a 48-month period after the first dose, and the frequency of incident and persistent vaccine targeted and non-targeted HPV infections in the different dose groups as the study progresses. In due course, we will document the frequency of CIN 2 and 3 caused by vaccine-targeted and non-targeted HPV types and, in the long-term, invasive cervical cancer incidence in the different dose groups over several years of follow-up
by linking with population-based cancer registries.
